Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanogen Extends IP Portfolio with Nucleic Acid Detection and Genotyping Technology Patents

Abstract:
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that it has been granted United States Patent No. 7,252,940, titled "Abasic site endonuclease assay" from the U.S. Patent and Trademark Office. The technology described in the patent extends the underlying proprietary real-time PCR technology used in the Company's MGB Alert® products to a new product offering that has been commercialized as research reagents for use in replication validation following genome wide scanning in pharmaceutical and biotechnology industry labs. This technology is also ideal for genetic analysis in multiplex formats of complex genetic diseases.

Nanogen Extends IP Portfolio with Nucleic Acid Detection and Genotyping Technology Patents

SAN DIEGO, CA | Posted on October 1st, 2007

The unique construct of these assay reagents provides researchers with a method for high throughput validation of SNPs (single nucleotide polymorphisms) discovered during genome wide scanning. The goal of many genome wide scanning projects is to identify SNPs associated with particular diseases, such as diabetes or heart failure, in order to identify therapeutic targets or develop diagnostic assays. In order to establish clear disease association, SNPs are validated across large sample populations, often on the order of tens of thousands. This newly patented technology provides the ability to test large numbers of SNPs in parallel across a large number of samples to complete validation in a relatively rapid manner.

Nanogen has also been awarded U.S. Patent No. 7,205,105, "Real-time linear detection probes: sensitive 5'-minor groove binder-containing probes for PCR analysis," related to the probes employed in its MGB Alert® line of reagents. These probes are an important part of the Company's proprietary product offering designed to assist clinical laboratories in developing molecular diagnostic tests that will detect genetic sequences associated with pathogens including those often tested in immunocompromised patients such as cytomegalovirus, Epstein-Barr virus, and enterovirus.

####

About Nanogen, Inc.
Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.

For more information, please click here

Contacts:
Nanogen, Inc.
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
Kelly Goodwin, Marketing Communications, 858-410-4688

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014

Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Announcements

NanoTechnology for Defense (NT4D) October 22nd, 2014

Mechanism behind nature's sparkles revealed October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Patents/IP/Tech Transfer/Licensing

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE